Sponsors must prepare for training on the new module and transition to its use for ASR submissions while ensuring all trial authorizations align with the timeline.
UKHSA has implemented control measures to destroy larvae and is monitoring the area closely for further mosquito activity.
Healthcare professionals and consumers are directed to report any adverse events related to the use of ZUBB Dietary Supplement to the FDA's MedWatch Program.
Update product labeling to include new efficacy data and boxed warnings, incorporate the new treatment into compliance protocols, and increase monitoring for adverse events associated with Etcamah.
Update labeling and monitoring protocols to include new prescribing information, dosage guidelines, and risk communications related to the potential cardiac risks associated with camizestrant.
Healthcare providers and compounding facilities should implement the new temporary policies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act to ensure compliance and access to essential nutrition products.
Healthcare professionals must act on the issued FSNs as outlined by MHRA, ensuring compliance to address any safety concerns associated with the listed medical devices.
Regulatory Affairs must implement the new compounding policies immediately to ensure compliance and mitigate risks associated with product availability.
